Myeloproliferative Neoplasms

Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Orca-Q Receives FDA RMAT Designation for High-Risk Hematologic Malignancies.

The FDA has approved a once-daily, extended-release formulation of ruxolitinib for select myelofibrosis, polycythemia vera, and graft-vs-host disease.

Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Aaron Gerds, MD, details the rationale behind investigating agents targeting CALR mutations and other novel therapies in myeloproliferative neoplasms.

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

Jan Philipp Bewersdorf, MD, FACP, detailed findings from a meta-analysis and considerations for the use of luspatercept for anemia in lower-risk MDS.

Use of ruxolitinib before, during, and after allogeneic stem cell transplant was associated with low rates of GVHD in myelofibrosis.

The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Selinexor plus ruxolitinib met the SVR co–primary end point but missed the symptom score end point in the phase 3 SENTRY trial in myelofibrosis.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Venetoclax plus decitabine/cedazuridine after a venetoclax-based RIC regimen was effective and safe in myelodysplastic syndromes or acute myeloid leukemia.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Allo-HSCT did not improve survival outcomes in patients with lower-risk myelodysplastic syndrome who had some higher-risk features.

Will the FDA approve rusfertide for the treatment of adult patients with polycythemia vera?

Luspatercept generated favorable efficacy and safety outcomes in the treatment of anemia in patients with transfusion-dependent, lower-risk MDS.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Nuvisertib was well tolerated with no dose-limiting toxicities and promising efficacy in relapsed/refractory myelofibrosis.